The Joy Plant

Opioids have been used for 5,000 years. Every generation has been told the new one is safe.

The Joy Plant is an analytical history of opioids — tracing the compound from Sumerian cultivation through Civil War battlefield medicine through Bayer's trademarked Heroin through the OxyContin epidemic through fentanyl — and documenting how each generation of institutional pharmacology used the same marketing language to introduce the same catastrophe under a different name.

This essay is part of The Pharmacological State — a documented history of institutional pharmacology. Each piece stands alone. The history is the argument.

The Brand

In 1898 a pharmaceutical company presented a new drug to the Congress of German Naturalists and Physicians and received a standing ovation.

The drug was ten times more effective than codeine as a cough suppressant. It was superior to morphine as a painkiller. It was — and this was the claim the audience applauded — completely non-addictive. The company had tested it on rabbits, frogs, and four of its own employees before making it commercially available. Within one year it was sold in 23 countries. The company was producing one ton of it annually.

The company was Bayer. The drug was Heroin. The name came from the German heroisch — meaning heroic, strong, powerful. Bayer named it for how it made people feel.

The addictive effects of morphine were already well known in 1898. Bayer knew this. The entire marketing strategy for Heroin was built on the premise that it was the safe non-addictive alternative to the compound that preceded it. Bayer advertised it to physicians, to families, to children. It came in tablets, in elixirs, in cough lozenges. It was endorsed by the Journal of the American Medical Association. It was recommended by the US Surgeon General. It was available over the counter.

That argument — the new compound is safer than what it replaces — would be made again with oxycodone in the 1950s, again with OxyContin in 1996, and again with every successive pharmaceutical opioid that followed. The language has not changed in 125 years. Only the compounds and the companies.

It took Bayer fifteen years to stop advertising Heroin as safe. By 1918 there were 200,000 addicts in New York City alone.

That same year the aspirin Bayer had released alongside Heroin was at the center of a separate crisis. The Spanish flu pandemic was killing hundreds of thousands. Medical authorities recommended aspirin at doses now known to be toxic — up to 31 grams per day against a maximum safe dose of approximately 4 grams. A peer-reviewed hypothesis published in Clinical Infectious Diseases in 2009 argues that those dosing recommendations may have contributed significantly to the pandemic's death toll — that the pulmonary edema documented in early deaths was consistent with salicylate toxicity, not influenza pathology alone. The hypothesis remains contested. What is not contested is that the company which gave the world Heroin and aspirin in the same year may have been implicated in two of the twentieth century's great pharmaceutical catastrophes simultaneously.

The Bayer name is on the bottle in your medicine cabinet. It has been there for 125 years.

The Joy Plant

The compound Bayer was selling as Heroin in 1898 was not new. It was the latest refinement of a plant that human civilization had been using for at least 5,000 years.

The Sumerians cultivated the opium poppy in lower Mesopotamia around 3,400 BCE and called it Hul Gil — the joy plant. That name is the oldest recorded description of opioid pharmacology in human history. Not a medical term. Not a clinical designation. A description of the feeling. The Sumerians knew exactly what the plant did and named it accordingly.

Egypt restricted opium to priests, magicians, and warriors. Its discovery was attributed to the god Thoth — the oldest recorded opioid prescription in history was a god giving another god opium for a headache. Cyprus was packaging opium in vessels shaped like poppy seed capsules by 1600 BCE — researchers call it prehistoric commodity branding. The compound was being marketed before the concept of marketing existed.

Opium moved along the Silk Road from Mesopotamia through Persia, India, and China. Greek and Roman physicians documented its uses. The Islamic world refined its applications. By medieval Europe it had become laudanum — opium dissolved in alcohol, available at every pharmacy, used by writers, artists, physicians, and housewives with equal accessibility and equal consequence. Thomas De Quincey wrote Confessions of an English Opium-Eater in 1821. Samuel Taylor Coleridge composed Kubla Khan under its influence. The poet, the philosopher, and the housewife were all using the same compound through the same retail channel with the same institutional blessing.

The question was never whether humans would use opioids. The archaeological record makes clear they always have. The question was always who would control the supply, who would profit from the demand, and what would happen to the population when the controlling institution decided the arrangement had become inconvenient.

That question has been answered the same way every time.

The Industrialization

The hypodermic needle arrived in 1853. Morphine — isolated from opium by a German pharmacist named Friedrich Sertürner in 1805 — could now be delivered directly into the bloodstream. The effect was immediate and profound in ways that oral opium administration had never been. Pain management was transformed.

Then the Civil War. Between 1861 and 1865 the Union Army alone requisitioned over 10 million opium pills and nearly 2.8 million ounces of opium powders and tinctures. A Confederate medical handbook of the era described opium as the most indispensable drug on the battlefield — important to the surgeon as gunpowder to the ordnance. Field surgeons injected morphine into soldiers with catastrophic wounds, amputations, and the dysentery and diarrheal diseases that moved through military camps with as much lethality as combat. The drug worked. Too well.

Veterans came home addicted. Tens of thousands of them — some estimates run higher, though the documentary record doesn't fully support the largest figures. The condition was named Soldier's Disease. Also army disease. The language captured something important — this was not individual moral failure or recreational excess. It was an institutional product. Military medicine had created a dependent population at a scale that had no precedent in American history, and sent that population home with no treatment, no understanding of what had happened to them, and no restriction on purchasing the compound that had made them dependent. Morphine and opium were available over the counter at pharmacies and through mail-order catalogs. The Sears Roebuck catalog later sold heroin.

This was America's first institutional opioid crisis. The institution that created it — military medicine — exited the arrangement when the war ended. The population it created was left to manage its dependence through whatever commercial channels were available.

The pattern was now established. It would repeat with remarkable consistency for the next 160 years.

The Safe Alternative

Bayer's Heroin was the first iteration of the safe alternative argument at industrial pharmaceutical scale. It was not the last.

The pattern was now set. The institution that had created the demand would change the rules. The population would be handed to whatever came next.

The Harrison Narcotics Tax Act of 1914 was the federal government's first attempt to regulate opioids. Its effect was not to treat the dependent population that military medicine and pharmaceutical commerce had created over the preceding half century. It was to criminalize that population. Doctors who had been legally prescribing opioids to maintain dependent patients — a common practice at the time — suddenly faced legal liability for doing so. The patients they had been treating had nowhere to go. The street market filled the gap immediately.

The pattern of institutional exit followed by market inheritance was playing out in real time. The institution that had normalized opioid use for fifty years changed the rules. The population that had been normalized into dependence under those rules was handed to the next institution — in this case, the illegal market.

Then the cycle reset. German pharmacologists synthesized oxycodone in 1916 as a less addictive alternative to morphine and heroin. It was not less addictive. The marketing language was already familiar. After World War II, new synthetic opioids were developed for wounded soldiers and the research cycle repeated — new compound, same language, same outcome.

In 1980 a letter published in the New England Journal of Medicine claimed that addiction was rare among hospital patients treated with opioids — fewer than one percent. The letter was four sentences long and was not a clinical study. It would be cited over 600 times in subsequent decades as evidence that opioids posed minimal addiction risk when used medically. The pain management movement of the 1980s and 1990s built substantially on that citation.

Pain was declared the fifth vital sign. Physicians were evaluated on their patients' pain scores. The pressure to prescribe increased systematically. The pharmaceutical industry was ready.

The Pharmaceutical Century

The pattern reset again. New compound. Same language. Same outcome.

In 1996 Purdue Pharma introduced OxyContin — a controlled-release formulation of oxycodone — and deployed a sales force with specific instructions. The drug was to be described as less than one percent addictive. Physicians who expressed concern about addiction were to be shown the 1980 New England Journal of Medicine letter. Sales representatives were paid bonuses based on prescription volume. The company spent $207 million on OxyContin promotion in 2001 alone — more than Eli Lilly spent promoting Prozac at its peak.

The Sackler family owned Purdue Pharma. They had made their first fortune in the 1950s and 1960s marketing Valium — the benzodiazepine that produced the first mass prescription tranquilizer dependence crisis in American history. Same family. Same playbook. Different compound. Different decade.

Internal Purdue documents later revealed in litigation showed the company understood OxyContin's addiction potential from early in its commercial life. A 1997 memo from a Purdue executive acknowledged that the drug was being abused. The marketing continued for years after the internal acknowledgment. Purdue eventually pleaded guilty to federal criminal charges of misbranding in 2007 and paid $600 million in fines. The marketing had generated over $35 billion in revenue. The fine was a cost of business.

By the time federal and state pressure forced meaningful restrictions on OxyContin prescribing in the early 2010s, millions of Americans had become opioid dependent through legitimate medical channels. Primary care physicians had been prescribing opioids for chronic pain at unprecedented rates. The dependent population was real, large, and suddenly facing a supply restriction it had no framework for managing.

The institution exited. The market was ready.

The Handoff

The institution exited. The market was ready.

When OxyContin became harder to obtain and reformulated versions became harder to abuse, the dependent population did not recover. It transitioned.

Mexican cartels — who had been building distribution infrastructure in American cities for two decades through the crack cocaine and methamphetamine markets — were already positioned. Black tar heroin moved into Midwestern and rural communities through the same channels that had distributed prescription opioids. The transition was documented and rapid. Communities in Ohio, West Virginia, and Kentucky that had been saturated with prescription opioids in the 2000s saw heroin availability surge in the early 2010s precisely as prescription supply tightened.

The population that pharmaceutical medicine had made opioid-dependent became the cartel's customer base. The handoff required no coordination between the institution and its successor. The demand existed. The supply followed.

Then fentanyl. The cartels had already proven with methamphetamine that a fully synthetic product — no agricultural supply chain, no poppy fields, no coca cultivation — offered dramatically better margins and dramatically better scalability. Fentanyl followed the same logic. Precursor chemicals sourced primarily from China. Synthesis in Mexican laboratories. A compound fifty times more potent than heroin deliverable in quantities that fit in an envelope.

The distribution infrastructure built during the crack epidemic carried all of it. The same networks that had moved cocaine in the 1980s, heroin in the 1990s, methamphetamine in the 2000s, and prescription opioids through diversion in the same period now carried fentanyl. The product had changed at each stage. The infrastructure was continuous.

The death toll from fentanyl exceeded 70,000 Americans in 2021 alone. The compound that the Sumerians called the joy plant — refined over 5,000 years of institutional pharmacology through military medicine, pharmaceutical marketing, and criminal distribution — was now killing more Americans annually than the entirety of the Vietnam War.

The Inheritance

Where the arc lands is not in the past.

The opioid-sensitized population that pharmaceutical medicine created, the cartel's fentanyl distribution made lethal, and the treatment industry now absorbs — that population did not disappear when the prescription supply tightened. It found alternatives.

Kratom extracts and 7-hydroxymitragynine entered a market that had been pharmacologically prepared for them. Partial opioid agonists arriving into a population with lowered receptor thresholds, established compression cycle behaviors, and a demonstrated willingness to source compounds outside conventional medical channels. The retail market for novel opioid-adjacent compounds is not a new phenomenon. It is the latest iteration of a pattern that runs from the Sumerian joy plant to a smoke shop in 2024.

The population was already conditioned to short-cycle opioid reinforcement. The compound didn't create the pattern. It fit into one that already existed. For the clinical framework that describes that pattern see Compressed-Cycle Opioid Dependence.

The Sumerians named it for how it made people feel. Bayer named it heroic. Purdue called it less than one percent addictive. The marketing language changes. The institutional pattern does not.

For the full framework see Institutional Pharmacology.

For the population this history produced see The Kindled Market